The clinical impact of pharmacogenetics on the treatment of epilepsy

Epilepsia

Volumn 50, Issue 1, 2009, Pages 1-23

  Löscher, Wolfgang ^a   Klotz, Ulrich ^b   Zimprich, Fritz ^c   Schmidt, Dieter ^d  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Epilepsy Research Group   (Germany)

Author keywords

Antiepileptic drugs; Drug resistance; Gene variation; Single nucleotide polymorphism; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DIAZEPAM; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOLIC ACID; GABAPENTIN; HLA B ANTIGEN; LAMOTRIGINE; MEPHENYTOIN; MULTIDRUG RESISTANCE PROTEIN 1; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADULT; ALLELE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DISEASE CONTROL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; EPILEPSY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GINGIVA HYPERPLASIA; HIGH RISK POPULATION; HLA SYSTEM; HUMAN; IMMUNE MEDIATED INJURY; LIVER TOXICITY; MACULOPAPULAR RASH; MEDICAL ETHICS; NEURAL TUBE DEFECT; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; SOCIAL ASPECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; URINARY EXCRETION; VISUAL FIELD DEFECT; VITAMIN SUPPLEMENTATION;

ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; DRUG RESISTANCE; EPILEPSY; GENOTYPE; HLA ANTIGENS; HUMANS; NERVE TISSUE PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SODIUM CHANNELS;

EID: 58149231251     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01716.x     Document Type: Review

References (178)

1. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M 2006a) HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7 : 813 818.
2. Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Kevin PB, Pirmohamed M 2006b) Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 16 : 287 296.
3. Anderle P, Huang Y, Sadee W 2004) Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur J Pharm Sci 21 : 17 24.
4. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K 2005) Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 78 : 559 581.
5. Aronica E, Yankaya B, Troost D, van Vliet EA, Lopes Da Silva FH, Gorter JA 2001) Induction of neonatal sodium channel II and III alpha-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur J Neurosci 13 : 1261 1266.
6. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D 2005) RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 6 : 61.
7. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, Nacak M, Roots I 1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48 : 409 415.
8. Bajpai M, Roskos LK, Shen DD, Levy RH 1996) Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 24 : 1401 1403.
9. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Löscher W 2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320 : 331 343.
10. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, Posavec A 2008) The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across blood-brain barrier in patients with generalized epilepsy. Seizure Eur J Epilepsy Mar 6; [Epub ahead of print].
11. Benbadis SR 2005) Practical management issues for idiopathic generalized epilepsies. Epilepsia 46 (Suppl 9 125 132.
12. Bernus I, Dickinson RG, Hooper WD, Eadie MJ 1997) The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol 44 : 21 27.
13. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T 1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45 : 348 355.
14. Bertilsson L, Baillie TA, Reviriego J 1990) Factors influencing the metabolism of diazepam. Pharmacol Ther 45 : 85 91.
15. Bertilsson L 1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29 : 192 209.
16. Bertrand D, Picard F, le Hellard S, Weiland S, Favre I, Phillips H, Bertrand S, Berkovic SF, Malafosse A, Mulley J 2002) How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia 43 (Suppl 5 112 122.
17. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R 2001) Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 70 : 391 394.
18. Brandt C, Bethmann K, Gastens AM, Löscher W 2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24 : 202 211.
19. A receptor subunit expression and function in temporal lobe epilepsy. Nat Med 4 : 1166 1172.
20. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Muller M 2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78 : 182 190.
21. Buehler BA, Delimont D, van Waes M, Finnell RH 1990) Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 322 : 1567 1572.
22. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P, Rozen R 1999) Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 84 : 151 157.
23. Christians U, Schmitz V, Haschke M 2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1 : 641 654.
24. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT 2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428 : 486.
25. Cotariu D, Zaidman JL 1988) Valproic acid and the liver. Clin Chem 34 : 890 897.
26. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D 2007) Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48 : 505 516.
27. Davis R, Peters DH, Mctavish D 1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 : 332 372.
28. Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD 1999) Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 56 : 216 220.
29. Delorey TM, Olsen RW 1999) GABA and epileptogenesis: comparing gabrb3 gene-deficient mice with Angelman syndrome in man. Epilepsy Res 36 : 123 132.
30. Depondt C 2006) The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 10 : 57 65.
31. Desta Z, Zhao X, Shin JG, Flockhart DA 2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41 : 913 958.
32. Ding X, Kaminsky LS 2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43 : 149 173.
33. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D 2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 : 1501 1506.
34. Duncan S, Mercho S, Lopes-Cendes I, Seni MH, Benjamin A, Dubeau F, Andermann F, Andermann E 2001) Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 42 : 750 753.
35. Duncan JS, Sander JW, Sisodiya SM, Walker MC 2006) Adult epilepsy. Lancet 367 : 1087 1100.
36. Duncan S 2007) Teratogenesis of sodium valproate. Curr Opin Neurol 20 : 175 180.
37. Ebid AH, Ahmed MM, Mohammed SA 2007) Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit 29 : 305 312.
38. Edwards SG, Hubbard V, Aylett S, Wren D 1999) Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med J 75 : 680 681.
39. Eikel D, Lampen A, Nau H 2006) Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19 : 272 278.
40. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M 2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45 : 737 744.
41. FDA (U.S. Food and Drug Administration) 2005) Guidance for industry: pharmacogenomic data submissions. http://www.fda.gov/cber/gdlns/pharmdtasub.htm.
42. FDA Alert [12/12/2007] 2007a) Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). http://www.fda.gov/cder/drug/ infopage/carbamazepine/defaulthtm.
43. FDA (U.S. Food and Drug Administration) 2007b) FDA approves updated warfarin (Coumadin) prescribing information. New genetic information may help providers improve initial dosing estimates of the anticoagulant for individual patients. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html.
44. Ferraro TN, Buono RJ 2005) The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav 7 : 18 36.
45. Ferraro TN, Dlugos DJ, Buono RJ 2006) Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics 7 : 89 103.
46. Finnell RH, Gelineau-van Waes J, Bennett GD, Barber RC, Wlodarczyk B, Shaw GM, Lammer EJ, Piedrahita JA, Eberwine JH 2000) Genetic basis of susceptibility to environmentally induced neural tube defects. Ann N Y Acad Sci 919 : 261 277.
47. Fromm MF 2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25 : 423 429.
48. Gardiner SJ, Begg EJ 2005) Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 15 : 365 369.
49. Gastaldi M, Bartolomei F, Massacrier A, Planells R, Robaglia-Schlupp A, Cau P 1997) Increase in mRNAs encoding neonatal II and III sodium channel alpha-isoforms during kainate-induced seizures in adult rat hippocampus. Brain Res Mol Brain Res 44 : 179 190.
50. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP 1991) Familial occurrence of hypersensitivity to phenytoin. Am J Med 91 : 631 634.
51. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W 2004) Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76 : 192 200.
52. Glaeser H, Drescher S, Eichelbaum M, Fromm MF 2005) Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 59 : 199 206.
53. Godard B, Cardinal G 2004) Ethical implications in genetic counseling and family studies of the epilepsies. Epilepsy Behav 5 : 621 626.
54. Goldstein DB, Need AC, Singh R, Sisodiya SM 2007) Potential genetic causes of heterogeneity of treatment effects. Am J Med 120 : S21 S25.
55. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K 2002) C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12 : 451 457.
56. Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK 1995) Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 50 : 1353 1359.
57. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O 1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39 : 508 512.
58. Hadama A, Ieiri I, Morita T, Kimura M, Urae A, Irie S, Kaneda T, Mamiya K, Tashiro N, Higuchi S, Otsubo K 2001) P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther Drug Monit 23 : 115 118.
59. Handforth A, Delorey TM, Homanics GE, Olsen RW 2005) Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome. Epilepsia 46 : 1860 1870.
60. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ 1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 337 : 275 283.
61. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB 2007) Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 80 : 876 883.
62. Ho PC, Abbott FS, Zanger UM, Chang TK 2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 3 : 335 342.
63. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U 2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 : 3473 3478.
64. Huber JD, Egleton RD, Davis TP 2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24 : 719 725.
65. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH 2004) Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 26 : 534 540.
66. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH 2005) Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6 : 411 417.
67. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT 2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16 : 297 306.
68. Hung CC, Jen TJ, Kao PJ, Lin MS, Liou HH 2007) Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8 : 1151 1158.
69. Iannetti P, Spalice A, Parisi P 2005) Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 : 967 969.
70. Ingelman-Sundberg M 2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25 : 193 200.
71. Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, Okuyama K, Tanaka E, Nakamura T, Kohda Y, Naito S, Miyabe M, Toyooka H 2005) CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 78 : 647 655.
72. Ito K, Suzuki H, Horie T, Sugiyama Y 2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22 : 1559 1577.
73. Jensen S, DiPaolo A, Lastella M, Erba P, Baldini M, Perini D, Pecori C, Danesi R, Iudice A, Mariani G, Del Tacca M, Murri L 2006) Pharmacogenetics of ABCB1 and brain kinetics of 99m-Tc-MIBI in epilepsy patients. Epilepsia 47 (Suppl. 3 88 89.
74. Kalow W 2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6 : 162 165.
75. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U 2001) The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1 : 204 210.
76. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA 2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11 : 803 808.
77. Kim DW, Kim M, Lee SK, Kang R, Lee SY 2006b) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 15 : 344 347.
78. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, Kim EY, Roh YI, Kim CJ 2006a) Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 15 : 67 72.
79. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM 2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 : 525 528.
80. Kinirons P, Cavalleri GL, Singh R, Shahwan A, Acheson JF, Wood NW, Goldstein DB, Sisodiya SM, Doherty CP, Delanty N 2006) A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 70 : 144 152.
81. Klotz U 2007) The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 46 : 271 279.
82. Komar AA 2007) Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8 : 1075 1080.
83. Kozma C 2001) Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 98 : 168 175.
84. Krauss G 2006) Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr 6 : 33 37.
85. Kultima K, Nystrom AM, Scholz B, Gustafson AL, Dencker L, Stigson M 2004) Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 112 : 1225 1235.
86. Kwan P, Brodie MJ 2001) Effectiveness of first antiepileptic drug. Epilepsia 42 : 1255 1260.
87. Kwan P, Brodie MJ 2005) Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46 : 224 235.
88. Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, Hui AC, Yu E, Wong LK 2007) Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 11 : 112 117.
89. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A 1999) Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 21 : 731 734.
90. Lazarowski A, Massaro M, Schteinschnaider A, Intruvini S, Sevlever G, Rabinowicz A 2004) Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther Drug Monit 26 : 44 46.
91. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C 2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48 Suppl 5 : 140 149.
92. Lee AY, Kim MJ, Chey WY, Choi J, Kim BG 2004) Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 60 : 155 159.
93. Leschziner G, Jorgensen AL, Andrew T, Pirmohamed M, Williamson PR, Marson AG, Coffey AJ, Middleditch C, Rogers J, Bentley DR, Chadwick DW, Balding DJ, Johnson MR 2006) Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol 5 : 668 676.
94. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR 2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7 : 154 179.
95. Lesko LJ 2007) Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 81 : 807 816.
96. Lewis LD 2005) Personalized drug therapy; the genome, the chip and the physician. Br J Clin Pharmacol 60 : 1 4.
97. Lin JH, Chiba M, Baillie TA 1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51 : 135 158.
98. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC 2006) A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J 6 : 265 268.
99. A receptor subtypes in human temporal lobe epilepsy. J Neurosci 20 : 5401 5419.
100. Löscher W, Potschka H 2005a) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76 : 22 76.
101. Löscher W, Potschka H 2005b) Drug resistance in brain diseases and the role of drug efflux transporters. Nature Rev Neurosci 6 : 591 602.
102. Malm H, Kajantie E, Kivirikko S, Kaariainen H, Peippo M, Somer M 2002) Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 59 : 630 633.
103. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N 1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39 : 1317 1323.
104. Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi S 2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55 : 821 825.
105. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH 2007) Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48 : 1015 1018.
106. Mann MW, Pons G 2007) Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs 21 : 143 164.
107. Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S, Vezzani A 2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46 : 1613 1619.
108. Marson AG, Al Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR 2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 : 1000 1015.
109. Marson AG, Al Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR 2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 : 1016 1026.
110. Marzolini C, Paus E, Buclin T, Kim RB 2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 : 13 33.
111. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK 2003a) Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 111 : 1393 1403.
112. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK 2003b) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63 : 732 741.
113. Nakajima Y, Saito Y, Shiseki K, Fukushima-Uesaka H, Hasegawa R, Ozawa S, Sugai K, Katoh M, Saitoh O, Ohnuma T, Kawai M, Ohtsuki T, Suzuki C, Minami N, Kimura H, Goto Y, Kamatani N, Kaniwa N, Sawada J 2005) Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 61 : 25 34.
114. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K 2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 : 297 303.
115. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, Stewart PA, Gaillard HL, Sachs ES, Wladimiroff JW 1992) The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 42 : 119 125.
116. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK 2001) Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 51 : 345 349.
117. Ozgon GO, Bebek N, Gul G, Cine N 2007) Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 59 : 67 70.
118. Phillips KA, Van Bebber SL 2005) Measuring the value of pharmacogenomics. Nat Rev Drug Discov 4 : 500 509.
119. Picard F, Bertrand S, Steinlein OK, Bertrand D 1999) Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 40 : 1198 1209.
120. Pirmohamed M, Lin K, Chadwick D, Park BK 2001) TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56 : 890 896.
121. Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D 2001) Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res 18 : 1126 1130.
122. Plummer NW, Meisler MH 1999) Evolution and diversity of mammalian sodium channel genes. Genomics 57 : 323 331.
123. Potschka H, Fedrowitz M, Löscher W 2001) P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12 : 3557 3560.
124. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, Heinemann U, Beck H 2003) A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 53 : 469 479.
125. Remy S, Beck H 2006) Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129 : 18 35.
126. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA 1987) Cytochrome P-450 - catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 235 : 890 893.
127. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A 2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22 : 5833 5839.
128. Rogawski MA, Löscher W 2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 : 553 564.
129. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C 2006) Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 123 : 665 670.
130. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE 1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283 : 698 703.
131. Sakaeda T, Nakamura T, Okumura K 2002) MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25 : 1391 1400.
132. Sankar R 2007) Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics. Acta Neurol Scand 116 : 65 71.
133. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD 2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77 : 503 514.
134. Schmidt D, Löscher W 2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 : 858 877.
135. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M 1998) Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51 : 1256 1262.
136. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K 2006) ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7 : 551 561.
137. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, McCarthy M, Kinirons P, Goldstein D, Delanty N 2007) The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res 73 : 192 198.
138. Shear NH, Spielberg SP 1988) Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 82 : 1826 1832.
139. Shostak S, Ottman R 2006) Ethical, legal, and social dimensions of epilepsy genetics. Epilepsia 47 : 1595 1602.
140. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM 2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348 : 1442 1448.
141. Sillanpaa M, Schmidt D 2006) Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 129 : 617 624.
142. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ 2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46 : 643 647.
143. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, Wieser HG, Pauli-Magnus C 2007) Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 115 : 232 242.
144. Sisodiya SM 2005) Genetics of drug resistance. Epilepsia 46 (Suppl 10 33 38.
145. Sisodiya S, Soranzo N, Wood NW, Goldstein DB 2005) Association of genetic loci: replication or not, that is the question. Neurology 64 : 1989.
146. Sisodiya SM, Goldstein DB 2007) Drug resistance in epilepsy: more twists in the tale. Epilepsia 48:2369-2370.
147. Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, Shiomi N, Kobayashi Y, Takashiba S, Shimizu K, Gomita Y, Oka E 2004) CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 74 : 827 834.
148. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB 2004) Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 14 : 1333 1344.
149. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, Kroetz DL, Goldstein DB, Sisodiya SM 2007) Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 48 : 674 683.
150. Steiger JL, Russek SJ 2004) GABAA receptors: building the bridge between subunit mRNAs, their promoters, and cognate transcription factors. Pharmacol Ther 101 : 259 281.
151. Su TZ, Feng MR, Weber ML 2005) Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther 313 : 1406 1415.
152. Summers MA, Moore JL, McAuley JW 2004) Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 : 1631 1634.
153. Svensson CK, Cowen EW, Gaspari AA 2001) Cutaneous drug reactions. Pharmacol Rev 53 : 357 379.
154. Szoeke CE, Newton M, Wood JM, Goldstein D, Berkovic SF, OBrien TJ, Sheffield LJ 2006) Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol 5 : 189 196.
155. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y 2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47 : 1427 1433.
156. Tan J, Liu Z, Nomura Y, Goldin AL, Dong K 2002) Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels. J Neurosci 22 : 5300 5309.
157. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF 2004) Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neuro-logy 63 : 1090 1092.
158. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB 2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102 : 5507 5512.
159. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH 2006) A common polymorphism in the SCN1A gene associates
160. Tate SK, Sisodiya SM 2007) Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 8 : 1441 1449.
161. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L 2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60 : 54 60.
162. Tomson T, Tybring G, Bertilsson L 1983) Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther 33 : 58 65.
163. Tong V, Teng XW, Chang TK, Abbott FS 2005) Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci 86 : 427 435.
164. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F 2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 : 203 209.
165. Urak L, Feucht M, Fathi N, Hornik K, Fuchs K 2006) A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. Hum Mol Genet 15 : 2533 2541.
166. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM 2008) Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 83 : 416 421.
167. Van Dyke DC, Ellingrod VL, Berg MJ, Niebyl JR, Sherbondy AL, Trembath DG 2000) Pharmacogenetic screening for susceptibility to fetal malformations in women. Ann Pharmacother 34 : 639 645.
168. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA 2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47 : 672 680.
169. van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, Wadman WJ, Gorter JA 2007) Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 322 : 141 147.
170. Vogel F 1959) Medizinische probleme der humangenetik. Med Kinderheilkunde 12 : 52 125.
171. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW 2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 : 535 541.
172. Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schroder E, Runge U, Jedlitschky G, Kroemer HK, Oertel J, Gaab MR, Pahnke J, Walker LC, Warzok RW 2004) Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 23 : 223 231.
173. Wilkinson GR 2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352 : 2211 2221.
174. Wray GA 2007) The evolutionary significance of cis-regulatory mutations. Nat Rev Genet 8 : 206 216.
175. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA 2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9 : 1142 1149.
176. Zaccara G, Franciotta D, Perucca E 2007) Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 : 1223 1244.
177. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C 2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63 : 1087 1089.
178. Zimprich F, Stogmann E, Bonelli SB, Baumgartner C, Mueller JC, Meitinger T, Zimprich A, Strom TM 2008) A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49:1108-1109.